Femasys Inc. Announces Financial Results for the Second Quarter Ended June 30, 2023 and Provides Corporate Update
- Patient enrollment has commenced in landmark pivotal trial for lead product...
Pregnancy
Published Analysis of Sotagliflozin (INPEFA(TM)) Clinical Data Demonstrates Significant Reductions in the Risk of Hospital Readmissions for Heart Failure
Post-Hoc Analysis of SOLOIST-WHF Clinical Data Published in Journal of the American College of Cardiology: Heart Failure Risk Reductions of...
BioSyent Launches Inofolic® for Women with Polycystic Ovary Syndrome (PCOS)
Approximately 1.4 million Canadian women have PCOS, and this unique soft-gel capsule is approved to help them manage their symptoms...
Rhythm Pharmaceuticals Announces Pre-Marketing Early Access Authorization for Setmelanotide for Use in Patients with Hypothalamic Obesity in France
-- Reimbursed early access program allows for patients with hypothalamic obesity in France to receive setmelanotide treatment ---- Early access...
FDA Approves ZURZUVAE™ (zuranolone), the First and Only Oral Treatment Approved for Women with Postpartum Depression, and Issues a Complete Response Letter for Major Depressive Disorder
Postpartum depression (PPD) approval based on results from two Phase 3 clinical trials; in the SKYLARK Study treatment with ZURZUVAE...
United States Women Health Laboratory Testing Research Report 2023-2028: Focus on Hereditary Cancer, Reproductive Health and Infectious Diseases, Prenatal Screening and Diagnostic Testing – ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--The "United States Women Health Laboratory Testing Market by Hereditary Cancer, Reproductive Health and Infectious Diseases, Prenatal Screening and...
Femasys Initiates Enrollment in Pivotal Trial of its Permanent Birth Control Candidate FemBloc
- First of its kind, non-surgical, permanent birth control option begins enrollment in landmark trial -ATLANTA, Aug. 03, 2023 (GLOBE...
Veru to Report Fiscal 2023 Third Quarter Financial Results on August 10, 2023
MIAMI, FL, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on...
Daré Bioscience Announces Grant Award Supporting Development of Potential New Therapeutic Intervention for the Prevention of Idiopathic Preterm Birth
Grant Funds Will Support Proof-of-Concept Target Validation Studies for Preclinical Development of a Potential New Approach for the Prevention and...
60 Degrees Pharmaceuticals Awarded Canadian Patent Covering Tafenoquine for Prevention of Malaria in Malaria-Naive Subjects
Patent provides exclusive use of tafenoquine for prevention of malaria in malaria-naive individuals in Canada until late 2035.Tafenoquine is the...
Lexicon Elects Diane E. Sullivan to Board of Directors
Ms. Sullivan brings her extensive commercialization, strategy, and market access experience to the Lexicon Board of DirectorsTHE WOODLANDS, Texas, July...
Gemina Laboratories Announces Major Breakthrough in Environmentally Friendly Lateral Flow Test Design by Removing the Requirement for Nitrocellulose
VANCOUVER, BC / ACCESSWIRE / July 25, 2023 / Gemina Laboratories Ltd. (CSE:GLAB)(FRA:8I7) (the "Company" or "Gemina") is excited to...
Emagine Solutions Technology Wins $1 Million in R&D Funding from the U.S. National Science Foundation
Latest fundraising effort to strengthen Emagine’s powerful suite of maternal health toolsTUCSON, Ariz.--(BUSINESS WIRE)--Emagine Solutions Technology has been awarded $1...
Following FDA Approval of YCANTH™ for the Treatment of Molluscum Contagiosum, Verrica Pharmaceuticals Enters into Non-Binding Term Sheet for up to $125 Million Debt Financing; Company to Host Conference Call and Webcast This Morning at 8:30 am ET
Term loan facility would provide for up to $125M in non-dilutive capital; $50M immediately available to Company following close of...
Genmab Announces AbbVie Receives Positive CHMP Opinion for Epcoritamab (TEPKINLY®) for the Treatment of Adults with Relapsed/Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL)
Company Announcement The positive CHMP opinion is supported by results from the EPCORE™ NHL-1 phase 1/2 trial evaluating the preliminary...
Emergent BioSolutions Receives U.S. FDA Approval of CYFENDUS™ (Anthrax Vaccine Adsorbed, Adjuvanted), previously known as AV7909, a Two-Dose Anthrax Vaccine for Post-Exposure Prophylaxis Use
Emergent has been delivering CYFENDUS™ vaccine to the U.S. Department of Health and Human Services since 2019, under pre-Emergency Use...
Rhythm Pharmaceuticals Announces Two Publications Detailing Burden of Hyperphagia and Obesity on Patients and Caregivers Living with Bardet-Biedl Syndrome
Results of The CAREgiver Burden in BBS (CARE-BBS) study show multifaceted burden of hyperphagiaBOSTON, July 19, 2023 (GLOBE NEWSWIRE) --...
Ovaterra’s Advanced Prenatal Vitamins Provide Full Daily Choline Recommendation for Breastfeeding Mothers
Research shows that taking the full daily recommended amount of choline can play a crucial role in supporting maternal health...
Slynd® (drospirenone) is now covered by the Régie de l’assurance maladie du Québec
Slynd® Slynd® is now reimbursed for 100% of Quebec women to whom it is indicated.BLAINVILLE, Quebec, July 12, 2023 (GLOBE...
Daré Bioscience to Present at the 9th Annual International Symposium of Drug Delivery Systems
SAN DIEGO, July 11, 2023 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today...